Here’s Why Cannabis Derivative Products Could Turn Out to Be the Next Big Thing

Learn how the regulation of derivative products could be a huge boon for the cannabis industry and how it stands to affect companies like Hexo Corp (TSX:HEXO).

| More on:

While still not legal yet within Canada for recreational consumption, the official legalization of cannabis derivative products appears to be right around the corner.

In this post, I’ll explain why nearly 12 months after recreational cannabis legalization, the market for derivative applications like edibles, oils, beverages, and creams could prove to be absolutely mind-blowing.

Last month, Health Canada released its outline on the final regulations and timeline for the introduction of cannabis edibles, beverages, topicals, and extracts.

Originally, when recreational pot became legal last October, regulators in Ottawa had yet to complete their formal consultations on what the rules for edibles and products should be.

That report was completed this past February with the current expectation for a limited supply of edibles and other derivative products to hit markets sometime this December.

As expected, there will be strict guidelines restricting concentration limits on the amount of THC per serving as well as restrictions limiting producers’ ability to market products that would appeal to youths.

Yet beyond the red tape, the market for cannabis edibles and other derivatives only continues to look more and more appealing.

Take, for example, licensed Canadian cannabis producer Hexo (TSX:HEXO).

HEXO, which inked a deal last year to pair with the world’s third-largest alcoholic brewer Molson Coors to jointly develop a line of cannabis-infused beverages for the recreational adult market, has made clear it has its sights are set on becoming the premier branded ingredients company for cannabis food products.

The company’s vision is to become the leading developer of products aimed at creating “consistent, quick-on and off cannabis experiences for sleep, sport, sex and fun” by working alongside potential Fortune 500 partners, like Molson Coors.

Not only do cannabis derivatives work effectively at creating a bigger overall market for the former Schedule 1 drug — for example, for users who may not feel comfortable inhaling a rolled cigarette or vape pen — but they offer significant advantages for producers as well, namely the prospect of higher margins and expanded profit potential.

Simply put, cannabis derivatives involve a significantly greater deal of processing before they’re ready for market.

That means they’re more expensive and complex to manufacture, but it also allows space for producers like HEXO and others to differentiate themselves, allowing them not only to charge a higher margin on their products but to differentiate themselves from a branding perspective as well, as evidenced in the aforementioned marketing pitch.

Foolish bottom line

Not only do cannabis derivatives offer the potential for producers to separate themselves from the pack, so to speak, but they also offer an avenue for the legal market as a whole to differentiate itself from the still-operating illicit market.

Not to mention that derivative applications also open a pathway for mega-brand consumer packaging goods companies to participate in the growing demand for licensed cannabis products.

The market for cannabis applications only continues to develop, and the latest regulations announced by Health Canada appear to suggest that this is a story that may not go away anytime soon.

Making the world smarter, happier, and richer.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jason Phillips owns shares of Molson Coors Brewing. The Motley Fool owns shares of Molson Coors Brewing.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »